LA PALMA, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback